

## CodeBreak200 (Amgen)

Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non-Small Cell Lung Cancer (NSCLC). This is the trial summary as assessed on clinicaltrials.gov on 13/08/2020.

Minor changes in the protocol may occur. You can check this on this direct link: <https://clinicaltrials.gov/ct2/show/NCT04303780?term=codebreak&recrs=ab&cond=Lung+Cancer&cntry=BE&draw=2&rank=1>

### Trial Design:

A Phase 3 Study to Compare AMG 510 with Docetaxel in Non Small Cell Lung Cancer (NSCLC) subjects with KRAS p. G12c mutation.

Arm	Intervention
Experimental AMG510	AMG 510
Comparator Docetaxel	Docetaxel

### Inclusion criteria:

- Men or women greater than or equal to 18 years old
- ECOG  $\leq$  1
- Pathologically documented, previously treated, locally-advanced and unresectable or metastatic NSCLC with KRAS p.G12C mutation confirmed through molecular testing

### Exclusion criteria:

- Active brain metastases
- Myocardial infarction within 6 months of study day 1
- Gastrointestinal (GI) tract disease causing the inability to take oral medication